Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026)
Anika Therapeutics' (ANIK) quarterly Change in Account Payables came in at $745000.0 in Q1 2026, up 1485.11% year-on-year from $47000.0 in Q1 2025, and down 15.05% on a QoQ basis from $877000.0 in Q4 2025.
Anika Therapeutics (ANIK) Change in Account Payables (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of Change in Account Payables data on file, last reported at $745000.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 1485.11% year-over-year to $745000.0 in Q1 2026; TTM through Mar 2026 was $740000.0, a 125.87% increase from a year earlier, with the FY2025 full-year figure at $42000.0, up 101.68% from the prior year.
- Change in Account Payables for Q1 2026 stood at $745000.0, down from $877000.0 in the prior quarter.
- Over the last five years, Change in Account Payables for ANIK reached as high as $1.4 million in Q4 2022 and fell as low as -$2.9 million in Q3 2024.
- Historically, Change in Account Payables has averaged $13823.5 across 5 years, with a median of $148000.0 in 2024.
- Across the five-year window, Change in Account Payables plunged 911.72% in 2024 and soared 1485.11% in 2026, its largest moves.
- Year by year, Change in Account Payables stood at $1.4 million in 2022, then declined by 8.66% to $1.3 million in 2023, then plunged by 109.25% to -$121000.0 in 2024, then soared by 824.79% to $877000.0 in 2025, then fell by 15.05% to $745000.0 in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $745000.0 in Q1 2026, $877000.0 in Q4 2025, and $231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Anika Therapeutics | 198.50 Mn | 131.71 Mn | 19.00 Mn | 745,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 745,000.00 |
| Mar 31, 2026 | 745,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Dec 31, 2025 | 877,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Sep 30, 2025 | 231,000.00 |
| Jun 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.11 Mn |
| Mar 31, 2025 | 47,000.00 |
| Mar 31, 2025 | 47,000.00 |
| Dec 31, 2024 | -121,000.00 |
| Dec 31, 2024 | -121,000.00 |
| Sep 30, 2024 | -2.93 Mn |
| Sep 30, 2024 | -2.93 Mn |
| Jun 30, 2024 | 148,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Mar 31, 2024 | 401,000.00 |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |